Human radiolabeled mass balance studies: objectives, utilities and limitations

Area of Science:

• Pharmacology
• Drug Metabolism
• Toxicology

Background:

• Metabolic pathways and metabolite profiles are critical for understanding drug effects and selecting appropriate animal models for toxicological studies.
• FDA guidance requires assessment of human oxidative metabolites with significant exposure in preclinical species.
• Metabolite exposure differences between humans and animals may necessitate additional toxicological testing.

Purpose of the Study:

• To examine the objectives, utilities, and limitations of radiolabeled mass balance studies.
• To provide guidance on performing and assessing these complex studies for drug development.
• To elucidate how these studies determine metabolite exposure in animals and humans.

Main Methods:

• Radiolabeled drugs are administered to preclinical species and humans.
• Biological fluids are collected and analyzed for total radioactivity.
• Quantitative metabolite profiles are evaluated to determine excretion rates, routes, and metabolic pathways.

Main Results:

• Mass balance studies provide critical information on drug metabolic pathways in both animals and humans.
• These studies are essential for regulatory submissions and drug approval processes.
• The data generated aids in understanding drug disposition and potential safety concerns.

Conclusions:

• Radiolabeled mass balance studies are indispensable for drug development, offering insights into metabolism and excretion.
• Despite their importance, there is a need for clearer guidance on conducting and interpreting these studies.
• Effective utilization of these studies is key to meeting regulatory requirements and ensuring drug safety.